ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Provided By GlobeNewswire
Last update: Sep 3, 2025
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);
No cases of amyloid-related imaging abnormalities (ARIA) observed to date;
Read more at globenewswire.com
